Mayer Brown advises the group Serb Pharmaceuticals on the structuring of the take-private of Y-mAb Therapeutics Inc.
Mayer Brown represented Serb Pharmaceuticals in the structuring of the take-private of Y-mAb Therapeutics Inc. (NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer.